Journal of Hepatology

Christophe Bureau, Danielle Adebayo, Mael Chalret de Rieu, Laure Elkrief, Dominique Valla, Markus Peck-Radosavljevic, Anne McCune, Victor Vargas, Macarena Simon-Talero, Juan Cordoba, Paolo Angeli, Silvia Rosi, Stewart MacDonald, Massimo Malago, Maria Stepanova, Zobair M Younossi, Claudia Trepte, Randall Watson, Oleg Borisenko, Sun Sun, Neil Inhaber, Rajiv Jalan
No abstract text is available yet for this article.
January 9, 2020: Journal of Hepatology
Fabienne Marcellin, Vincent Di Beo, Hugues Aumaitre, Marion Mora, Linda Wittkop, Claudine Duvivier, Camelia Protopopescu, Karine Lacombe, Laure Esterle, Cyril Berenger, Camille Gilbert, Olivier Bouchaud, Isabelle Poizot-Martin, Philippe Sogni, Dominique Salmon-Ceron, Patrizia Carrieri
No abstract text is available yet for this article.
January 7, 2020: Journal of Hepatology
Hsiao-Yen Ma, Gen Yamamoto, Jun Xu, Xiao Liu, Daniel Karin, Ju Youn Kim, Ludmil B Alexandrov, Yukinori Koyama, Takahiro Nishio, Chris Benner, Sven Heinz, Sara B Rosenthal, Shuang Liang, Mengxi Sun, Gabriel Karin, Peng Zhao, Pnina Brodt, Iain H Mckillop, Oswald Quehenberger, Ed Dennis, Alan Saltiel, Hidekazu Tsukamoto, Bin Gao, Michael Karin, David A Brenner, Tatiana Kisseleva
BACKGROUND&AIMS: Chronic alcohol (EtOH) consumption is a leading risk factor for development of hepatocellular carcinoma (HCC), which is associated with marked increase of hepatic expression of pro-inflammatory IL-17A and its receptor IL-17RA. METHODS: Genetic deletion and pharmacological blocking was used to characterize the role of IL-17A/IL-17RA signaling in the pathogenesis of HCC. RESULTS: We demonstrate that global deletion of IL-17RA gene suppressed HCC in alcohol-fed DEN-challenged IL-17RA-/- and Mup-uPA/IL-17RA-/- mice compared to wild type mice...
December 31, 2019: Journal of Hepatology
W Q Dai, L Xu, X N Yu, G C Zhang, H Y Guo, H L Liu, G Q Song, S Q Weng, L Dong, J M Zhu, T T Liu, C Y Guo, X Z Shen
BACKGROUND & AIMS: Mitochondrial dysfunction and subsequent metabolic deregulation are commonly observed in cancers including hepatocellular carcinoma (HCC). When mitochondrial function is impaired, reductive glutamine metabolism is a major cellular carbon source for de novo lipogenesis to support cancer cell growth. The underlying regulators of reductively metabolized glutamine in mitochondrial dysfunction are not completely understood in tumorigenesis including in HCC. METHODS: We systematically investigated the role of oxoglutarate dehydrogenase-like (OGDHL), one of the rate-limiting components of the key mitochondrial multi-enzyme OGDH complex (OGDHC), in the regulation of lipid metabolism in hepatoma cells and explored the underlying molecular mechanisms...
December 30, 2019: Journal of Hepatology
Elsemieke de Vries, Ulrich Beuers
No abstract text is available yet for this article.
December 28, 2019: Journal of Hepatology
Donna M Evon, Souvik Sarkar, Jipcy Amador, Anna S Lok, Richard K Sterling, Paul W Stewart, Bryce B Reeve, Marina Serper, Nancy Reau, K Rajender Reddy, Adrian M Di Bisceglie, David R Nelson, Carol E Golin, Joseph K Lim, Michael W Fried
No abstract text is available yet for this article.
December 27, 2019: Journal of Hepatology
Liang-Qing Dong, Li-Hua Peng, Li-Jie Ma, Dong-Bing Liu, Shu Zhang, Shu-Zhen Luo, Jun-Hua Rao, Hong-Wen Zhu, Shuai-Xi Yang, Shui-Jun Xi, Min Chen, Fan-Fan Xie, Fu-Qiang Li, Wen-Hui Li, Chen Ye, Li-Ya Lin, Yu-Jue Wang, Xiao-Ying Wang, Da-Ming Gao, Hu Zhou, Huan-Ming Yang, Jian Wang, Shi-da Zhu, Xiang-Dong Wang, Ya Cao, Jian Zhou, Jia Fan, Kui Wu, Qiang Gao
BACKGROUND AIMS: Multifocal tumors, developed either from intrahepatic metastasis (IM) or multicentric occurrence (MO), is a distinct feature of hepatocellular carcinoma (HCC). Immunogenomic characterization of multifocal HCC is important for understanding immune escape in different lesions and developing immunotherapy. METHODS: We combined whole exome/transcriptome sequencing, multiplex immunostaining, immunopeptidomes, T-cell receptor (TCR) sequencing and bioinformatic analyses of 47 tumors from 15 HCC patients with multifocal lesions...
December 27, 2019: Journal of Hepatology
Stephen A Harrison, Zachary Goodman, Abdul Jabbar, Ravi Vemulapalli, Ziad H Younes, Bradley Freilich, Muhammad Y Sheikh, Jörn M Schattenberg, Zeid Kayali, Adam Zivony, Aasim Sheikh, Javier Garcia-Samaniego, Sanjaya K Satapathy, George Therapondos, Edward Mena, Detlef Schuppan, James Robinson, Jean L Chan, David T Hagerty, Arun J Sanyal
BACKGROUND AND AIMS: Non-alcoholic steatohepatitis (NASH) is characterized by hepatocyte steatosis, ballooning, and lobular inflammation which may lead to fibrosis. Lipotoxicity activates caspases, which cause apoptosis and inflammatory cytokine (IL-1β and IL-18) production. Emricasan is a pan-caspase inhibitor that decreases serum aminotransferases and caspase activation in NASH patients. This study postulated that 72 weeks of emricasan treatment would improve liver fibrosis without worsening of NASH...
December 27, 2019: Journal of Hepatology
Anita Paisant, Valérie Vilgrain, Jérémie Riou, Frédéric Oberti, Olivier Sutter, Valérie Laurent, Agnès Rodes, Boris Guiu, Christophe Cassinotto, Hervé Trillaud, Yvan Bricault, Sophie Michalak, Onorina Bruno, Maxime Ronot, Christophe Aubé
BACKGROUND & AIMS: The aim of this study was to compare the performance of MRIs with extracellular contrast agents (ECA-MRI) to HB contrast agents (HBA-MRI) for the non-invasive diagnosis of small HCCs in a head-to-head comparison. METHODS: Between August 2014 and October 2017; 171 cirrhotic patients, each with 1 to 3 nodules measuring 1 to 3 cm, were included across eight centers. All patients had both an ECA-MRI and an HBA-MRI within a month. The non-invasive diagnosis of HCC was made when the nodule was hyper-enhanced at the arterial phase (HA) with wash-out at the portal phase (PP) and/or delayed phase (DP) for the ECA-MRI, or PP and/or HB phase (HBP) for the HBA-MRI...
December 20, 2019: Journal of Hepatology
Guadalupe Garcia-Tsao, Jaime Bosch, Zeid Kayali, Stephen A Harrison, Manal F Abdelmalek, Eric Lawitz, Sanjaya K Satapathy, Marwan Ghabril, Mitchell L Shiffman, Ziad H Younes, Paul J Thuluvath, Annalisa Berzigotti, Agustin Albillos, James M Robinson, David T Hagerty, Jean L Chan, Arun J Sanyal
BACKGROUND AND AIM: Emricasan, an oral pan-caspase inhibitor, decreased portal pressure in experimental cirrhosis and in patients with cirrhosis and portal pressure (assessed by the hepatic venous pressure gradient [HVPG]) ≥12 mmHg. We aimed to confirm these results in a randomized, placebo-controlled, double blind study. METHODS: Multicenter study including 263 patients with cirrhosis due to non-alcoholic steatohepatitis (NASH) and baseline HVPG ≥12 mmHg randomized 1:1:1:1 to emricasan 5 (n=65), 25 (n=65), 50 (n=66) mg or placebo (n=67) orally twice daily for up to 48 weeks...
December 20, 2019: Journal of Hepatology
Kate Childs, Mary Cannon, Christopher Davis, Emma C Thompson, Geoff Dusheiko, Kosh Agarwal
No abstract text is available yet for this article.
December 20, 2019: Journal of Hepatology
Pramod Kumar, Anand Kulkarni
No abstract text is available yet for this article.
December 18, 2019: Journal of Hepatology
Yong-Xiang Wang, Matthias Niklasch, Tiantian Liu, Yang Wang, Bisheng Shi, Wenjie Yuan, Thomas F Baumert, Zhenghong Yuan, Shuping Tong, Michael Nassal, Yu-Mei Wen
BACKGROUND AND AIM: Noncytolytic curing of hepatitis B virus (HBV) infected hepatocytes by cytokines including type I interferons (IFNs) is of importance for resolving acute and chronic infection. However, as IFNs stimulate hundreds of genes those most relevant for HBV suppression remain largely unknown. Amongst them are the large Mx GTPases. Human MX1 (or MxA) is active against many RNA viruses while MX2 (or MxB) was recently found to restrict human immunodeficiency virus 1, hepatitis C virus, and herpesviruses...
December 18, 2019: Journal of Hepatology
Théo Z Hirsch, Ana Negulescu, Barkha Gupta, Stefano Caruso, Bénédicte Noblet, Gabrielle Couchy, Quentin Bayard, Léa Meunier, Guillaume Morcrette, Jean-Yves Scoazec, Jean-Frédéric Blanc, Giuliana Amaddeo, Jean-Charles Nault, Paulette Bioulac-Sage, Marianne Ziol, Aurélie Beaufrère, Valérie Paradis, Julien Calderaro, Sandrine Imbeaud, Jessica Zucman-Rossi
BACKGROUND AND AIMS: DNAJB1-PRKACA fusion is a specific driver event in fibrolamellar carcinoma (FLC), a rare subtype of hepatocellular carcinoma (HCC) occurring in adolescents and young adults. In older patients, molecular determinants of HCC with mixed histological features of HCC and FLC (mixed-FLC/HCC) remain to be discovered. METHODS: A series of 151 liver tumors including 126 HCC, 15 FLC, and 10 mixed-FLC/HCC were analyzed by RNAseq and whole-genome- or whole-exome-sequencing...
December 17, 2019: Journal of Hepatology
Fabio Nascimbeni, Pierre Bedossa, Larysa Fedchuk, Raluca Pais, Frédéric Charlotte, Pascal Lebray, Thierry Poynard, Vlad Ratziu
BACKGROUND AND AIMS: Histological classifications used to diagnose/stage nonalcoholic fatty liver disease (NAFLD) are based on morphology, thus empirical, with undetermined clinical correlates and relevance. We assessed the clinical relevance of the fatty liver inhibition of progression (FLIP) algorithm and the steatosis, activity and fibrosis (SAF) scoring system. METHODS: 140 consecutive patients with suspected NAFLD and a separate validation cohort of 78 patients enrolled in a therapeutic trial, all with central reading of liver biopsy, were included...
December 17, 2019: Journal of Hepatology
Elske Hoornenborg, Liza Coyer, Anders Boyd, Roel Christiaan Alfons Achterbergh, Maarten Franciscus Schim van der Loeff, Sylvia Bruisten, Henry John Christiaan de Vries, Jelle Koopsen, Thijs Jw van de Laar, Maria Prins
BACKGROUND AND AIMS: Hepatitis C virus (HCV) has emerged as a sexually transmitted infection (STI) among HIV-positive men who have sex with men (MSM). We evaluated HCV-incidence and its risk-factors among HIV-negative MSM using HIV pre-exposure prophylaxis (PrEP). METHODS: Participants of the Amsterdam PrEP project were tested for HCV antibodies or HCV-RNA every 6 months. Participants used daily or event-driven PrEP and could switch regimens during follow-up. We calculated incidence rates (IRs) for overall HCV-infection and separately for primary and re-infection...
December 17, 2019: Journal of Hepatology
Zechuan Zhang, Xiaoliang Xu, Wenfang Tian, Runqiu Jiang, Yijun Lu, Qikai Sun, Rao Fu, Qifeng He, Jincheng Wang, Yang Liu, Hailong Yu, Beicheng Sun
BACKGROUND & AIMS: Non-alcoholic steatohepatitis (NASH) is associated with dysregulation of lipid metabolism and hepatic inflammation. The causal mechanism underlying NASH is not fully elucidated. We aim to investigate the role of β-arrestin1 (ARRB1) in the progression of NASH. METHODS: Human liver tissues from patients with NASH and control subjects were obtained to evaluate ARRB1 expression. NASH models were established in ARRB1 knockout and wild type mice fed high-fat diet (HFD) for 26 weeks or methionine/choline deficient (MCD) diet for 6 weeks...
December 16, 2019: Journal of Hepatology
Terry Cheuk-Fung Yip, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Yee-Kit Tse, Lilian Yan Liang, Vicki Wing-Ki Hui, Hye Won Lee, Grace Chung-Yan Lui, Henry Lik-Yuen Chan
BACKGROUND & AIMS: PAGE-B and modified PAGE-B (mPAGE-B) scores are developed to predict risk of hepatocellular carcinoma (HCC) in patients on nucleos(t)ide analogue therapy. However, how and when to use these risk scores in clinical practice is uncertain. METHODS: Consecutive adult patients with chronic hepatitis B who had received entecavir or tenofovir for at least 6 months between January 2005 and June 2018 were identified from a territory-wide database in Hong Kong...
December 16, 2019: Journal of Hepatology
Anil Dhawan, Nataruks Chaijitraruch, Emer Fitzpatrick, Sanjay Bansal, Celine Filippi, Sharon C Lehec, Nigel D Heaton, Pauline Kane, Anita Verma, Robin D Hughes, Ragai R Mitry
BACKGROUND: Liver transplantation (LT) is the most effective treatment for patients with acute liver failure (ALF) though with the limitations of surgical risks and the need for life-long immunosuppression. Transplantation of microencapsulated human hepatocytes in alginate is an attractive option over whole liver replacement. The safety and efficacy of hepatocyte microbeads transplanted intraperitoneally has been shown in animal models. We report our experience of the use of this therapy in children with ALF on named patient basis under a MHRA Specials Manufacture License...
December 13, 2019: Journal of Hepatology
Victor Sapena, Jose Rios, Ferran Torres, Zoe Mariño, Xavier Forns, Jordi Bruix, Maria Reig
No abstract text is available yet for this article.
December 13, 2019: Journal of Hepatology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"